Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ROBAXIN vs CARISOPRODOL AND ASPIRIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Centrally acting muscle relaxant; depresses polysynaptic reflexes at spinal cord and supraspinal levels, possibly via glycine receptor agonism and GABAergic modulation.
Carisoprodol is a centrally acting muscle relaxant that modulates GABA-A receptor activity and may act as a weak partial agonist at the central nervous system. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis, which results in analgesic, antipyretic, and anti-inflammatory effects.
Relief of discomfort associated with acute, painful musculoskeletal conditions,Adjunct to rest, physical therapy, and other measures
Relief of discomfort associated with acute painful musculoskeletal conditions
1500 mg orally 4 times daily, or 750 mg orally every 4 hours as needed. Maximum 6 g/day. For IV use: 1 g (10 m L) as a single intravenous injection or infusion.
1-2 tablets (carisoprodol 200 mg / aspirin 325 mg) orally 4 times daily.
1-2 hours in adults; clinically, multiple daily dosing required to maintain effect.
Carisoprodol: 1.5-2 hours (terminal half-life), but active metabolite meprobamate has half-life of 9-12 hours, contributing to prolonged sedation. Aspirin: 15-20 minutes (parent drug); salicylate: 2-3 hours at low doses, 15-30 hours at high doses due to saturable hepatic metabolism.
Hepatic metabolism via CYP450 enzymes (primarily CYP1A2, CYP3A4); active metabolite (methocarbamol).
Carisoprodol is N-deacetylated via CYP2C19 to meprobamate, a schedule IV controlled substance. Aspirin is hydrolyzed to salicylic acid in the liver and gastrointestinal tract.
Renal excretion of metabolites accounts for 99% of elimination; <1% excreted as unchanged drug in urine.
Carisoprodol: Renal excretion of metabolites (hydroxycarisoprodol, meprobamate) and <1% unchanged. Aspirin: Renal excretion of salicylate and metabolites (salicyluric acid, gentisic acid); ~80% renal, with dose-dependent elimination via first-order and Michaelis-Menten kinetics.
50% bound to albumin.
Carisoprodol: ~60% bound to albumin. Aspirin: 80-90% bound to albumin (salicylate); highly protein-bound at therapeutic concentrations.
0.5-1.0 L/kg; indicates distribution into total body water.
Carisoprodol: ~0.7 L/kg (large Vd, extensive tissue distribution). Aspirin: ~0.15 L/kg (salicylate; low Vd, primarily in extracellular fluid). Clinical meaning: Carisoprodol distributes into CNS and muscle; aspirin remains largely in plasma and interstitial space.
Oral: 80-100% (extensive absorption, first-pass metabolism minimal).
Oral: Carisoprodol: ~90% (well absorbed). Aspirin: ~40-50% (presystemic hydrolysis in GI mucosa and liver; rectal: 100% absorbed, but avoids first-pass).
In severe renal impairment (Cr Cl <30 m L/min), reduce dose by 50% and monitor for CNS effects. Avoid use in anuria.
e GFR 30-59 m L/min: avoid or reduce dose; e GFR <30 m L/min: contraindicated.
Contraindicated in severe hepatic impairment (Child-Pugh class C). Use with caution in mild to moderate impairment; reduce dose by 50% and monitor for sedation.
Child-Pugh Class A: caution; Class B or C: contraindicated.
Not recommended for children under 12 years. For ages ≥12 years: same as adult dosing.
Not recommended for pediatric patients under 12 years of age. For older adolescents, weight-based dosing of aspirin 10-15 mg/kg/dose every 4-6 hours (max 80 mg/kg/day) and carisoprodol 5-10 mg/kg/dose three times daily; avoid routine use due to risk of Reye's syndrome.
Initiate at reduced dose (e.g., 750 mg 4 times daily) due to increased sensitivity and risk of sedation; titrate cautiously and monitor renal function.
Initiate at lowest effective dose; monitor for CNS depression, renal function, and bleeding risk. Avoid in patients with significant renal impairment or peptic ulcer disease.
None
None.
May cause drowsiness or dizziness; caution with driving or operating machinery,Risk of serotonin syndrome with concomitant serotonergic drugs,Hepatic impairment; monitor liver function,Renal impairment; caution in severe cases,Use with caution in elderly and debilitated patients
Dependence and withdrawal: Carisoprodol may cause dependence and withdrawal symptoms.,Sedation and CNS depression: Additive effects with alcohol and other CNS depressants.,Reye's syndrome: Aspirin use in children and teenagers with viral illness.,Gastrointestinal bleeding: Aspirin increases risk of GI bleeding.,Hypersensitivity reactions: Anaphylaxis, angioedema.
Hypersensitivity to methocarbamol or any component,Myasthenia gravis,Known hypersensitivity to cyclobenzaprine or related compounds (if formulation includes)
Hypersensitivity to carisoprodol or aspirin.,Children and teenagers with viral infections (Reye's syndrome risk).,Active peptic ulcer disease or GI bleeding.,Severe hepatic impairment.,History of asthma induced by aspirin or NSAIDs.,Concomitant use with meprobamate-containing products.
No significant food interactions. However, take with food if gastrointestinal upset occurs. Avoid alcohol.
Avoid alcohol. Take with food or milk to reduce gastrointestinal irritation. Avoid high-tyramine foods (e.g., aged cheese, cured meats) as aspirin may potentiate tyramine effects.
No adequate well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Risk cannot be ruled out. Use only if clearly needed. First trimester: potential risk unknown. Second and third trimesters: may be associated with neonatal respiratory depression if used near delivery.
First trimester: Aspirin associated with increased risk of neural tube defects and gastroschisis; carisoprodol limited data. Second and third trimesters: Aspirin use increases risk of premature closure of ductus arteriosus and oligohydramnios; carisoprodol not well studied but may cause neonatal withdrawal. Avoid in third trimester due to aspirin's antiprostaglandin effects.
Methocarbamol is excreted in human milk in small amounts. The M/P ratio is unknown. Caution should be exercised when administered to a nursing woman. Monitor infant for sedation.
Aspirin and carisoprodol are excreted into breast milk. M/P ratio for aspirin is approximately 0.6-0.9; carisoprodol M/P ratio not established. Risk of Reye syndrome with aspirin, neonatal salicylate accumulation, and sedation from carisoprodol. Use not recommended during breastfeeding.
No specific dosing adjustments are recommended due to lack of pharmacokinetic data in pregnancy. Use lowest effective dose for shortest duration.
Pregnancy increases clearance of aspirin and carisoprodol; however, avoid use due to fetal risks. No recommended dose adjustments; contraindicated, especially in third trimester.
ROBAXIN (methocarbamol) is a centrally acting muscle relaxant indicated for acute musculoskeletal pain. Onset of action is within 30 minutes; peak effect at 2 hours. Avoid in patients with myasthenia gravis. Renal impairment requires dose adjustment. Can cause sedation; avoid concurrent CNS depressants. IV formulation may cause hemolysis if extravasation occurs.
Carisoprodol is metabolized to meprobamate, a controlled substance; monitor for abuse potential. Aspirin increases bleeding risk; avoid in children with viral illness due to Reye's syndrome. Combination may cause CNS depression and impaired motor function. Use with caution in renal impairment.
Drowsiness and dizziness are common; do not drive or operate machinery until you know how this medication affects you.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids).,Take exactly as prescribed; do not increase dose or frequency.,May cause urine discoloration (brown, black, or blue-green); this is harmless.,Notify your doctor if you experience rash, itching, or difficulty breathing.,Do not stop abruptly; taper dose if discontinuing after prolonged use.
Do not drive or operate machinery until you know how this medication affects you.,Avoid alcohol and other CNS depressants while taking this medication.,Take with food or milk to reduce stomach upset.,Do not use in children or teenagers with flu-like symptoms or chickenpox due to risk of Reye's syndrome.,Report signs of bleeding (easy bruising, black stools, vomiting blood) or allergic reactions (rash, swelling, difficulty breathing).,Rapid discontinuation may cause withdrawal symptoms (anxiety, insomnia, muscle twitching).
No interactions on record
"The co-administration of pentobarbital, a barbiturate and potent CYP3A4 inducer, with carisoprodol, a prodrug that is metabolized to its active form, meprobamate, via CYP2C19, may lead to reduced plasma concentrations of meprobamate due to pentobarbital-induced upregulation of CYP2C19, potentially diminishing the sedative and muscle relaxant effects of carisoprodol. However, pentobarbital also acts as a central nervous system (CNS) depressant, and additive CNS depression can occur, increasing the risk of excessive sedation, respiratory depression, and impairment of psychomotor function. Clinical outcomes may include altered therapeutic efficacy of carisoprodol and heightened risk of CNS and respiratory adverse effects."
"Carisoprodol, a centrally acting skeletal muscle relaxant, is metabolized primarily by CYP2C19 to its active metabolite meprobamate. Isoniazid, a first-line antitubercular agent, is a known inhibitor of CYP2C19. When coadministered, isoniazid can decrease the metabolism of carisoprodol, leading to increased plasma concentrations of both carisoprodol and meprobamate. This elevation raises the risk of dose-related adverse effects such as sedation, dizziness, and respiratory depression, and may prolong the duration of muscle relaxant action."
"The combination of sulpiride, an atypical antipsychotic with dopamine D2 receptor antagonism and mild serotonin 5-HT4 agonist properties, and carisoprodol, a centrally acting muscle relaxant metabolized to meprobamate (a barbiturate-like sedative-hypnotic), can result in additive central nervous system (CNS) depression, including sedation, dizziness, and psychomotor impairment. Additionally, both drugs may lower the seizure threshold, increasing the risk of seizures. Sulpiride can also prolong the QT interval, and carisoprodol's sedative effects may mask or exacerbate this cardiotoxicity, potentially leading to ventricular arrhythmias such as torsade de pointes."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ROBAXIN vs CARISOPRODOL AND ASPIRIN, answered by our medical review team.
ROBAXIN is a Skeletal Muscle Relaxant that works by Centrally acting muscle relaxant; depresses polysynaptic reflexes at spinal cord and supraspinal levels, possibly via glycine receptor agonism and GABAergic modulation.. CARISOPRODOL AND ASPIRIN is a Skeletal Muscle Relaxant that works by Carisoprodol is a centrally acting muscle relaxant that modulates GABA-A receptor activity and may act as a weak partial agonist at the central nervous system. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis, which results in analgesic, antipyretic, and anti-inflammatory effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ROBAXIN and CARISOPRODOL AND ASPIRIN depend on the specific clinical indication. These are both Skeletal Muscle Relaxant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ROBAXIN is: 1500 mg orally 4 times daily, or 750 mg orally every 4 hours as needed. Maximum 6 g/day. For IV use: 1 g (10 m L) as a single intravenous injection or infusion.. The standard adult dose of CARISOPRODOL AND ASPIRIN is: 1-2 tablets (carisoprodol 200 mg / aspirin 325 mg) orally 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ROBAXIN and CARISOPRODOL AND ASPIRIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ROBAXIN is classified as Category C. No adequate well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Risk cannot be ruled out. Use only if clearly needed. First trimester: p. CARISOPRODOL AND ASPIRIN is classified as Category A/B. First trimester: Aspirin associated with increased risk of neural tube defects and gastroschisis; carisoprodol limited data. Second and third trimesters: Aspirin use increases risk. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.